Listings and information about scientific presentations of results from analysis of the FHSC global registry.
Presentations: 90th EAS Congress
The latest global collaborative work of the FHSC was represented at the EAS 90th Congress, May 2022, Milan Italy, via two well-received talks:
- Kanika Dharmayat et al. on behalf of EAS FHSC Investigators. Global perspective of paediatric Familial Hypercholesterolaemia: Analysis from the EAS FHSC Registry on over 11,200 children and adolescents with Heterozygous Familial Hypercholesterolaemia from 44 countries.
Late Breaker at EAS 90th Congress 2022, Milan Italy.
- Antonio J. Vallejo-Vaz et al. on behalf of EAS FHSC Investigators. Identification, characteristics and management of adults with heterozygous familial hypercholesterolaemia in high and non-high income countries participating in the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Science at Glance at EAS 90th Congress 2022, Milan Italy.
89th EAS Congress 2021
Next steps after the Global Call to Action
- During the EAS virtual congress 2021 a joint discussion was held hosted by the EAS and the World Heart Federation (WHF), which brought together the international key stakeholders to discuss and debate on the progress made since the launch of the 2020 Global Call to Action on FH.
IAS/EAS Joint session Universal cardiovascular health – time to act
- Implications of the EAS FHSC to guiding global policy on FH, By Antonio Vallejo-Vaz was presented in the IAS/EAS Joint Session: Universal cardiovascular health – time to act
88th EAS Congress 2020
The latest global collaborative work of the FHSC was represented in two presentations:
- Abstract : ”Characteristics of Adults with Heterozygous Familial Hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC Global Registry on over 36,000 cases of Familial Hypercholesterolaemia”. Oral presentation in a workshop session.
- Abstract : ”Heterozygous Familial Hypercholesterolaemia in Children: Preliminary analysis from the EAS FHSC Global Registry on over 7,900 children with Familial Hypercholesterolaemia”. Oral presentation in a Science at a Glance session.
ESC Congress 2019 Paris
Monday 2nd September 2019 – The first patient data from the European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry on FH, highlight the need for more intensive therapy to reduce low-density lipoprotein cholesterol (LDL C), ‘bad cholesterol‘, in people with FH. Among 42,000 adults with heterozygous FH, only about half received a statin at the time of entry to the registry. Of people on a statin, over 85 per cent had LDL-C levels at entry that were above European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) recommended targets for people with FH. The findings were reported during the ESC Congress, 31 August-4 September, Paris, France.
- Late-breaking session: Risk Factors and Prevention The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries
- EAS/ESC joint session on FH Expert Advice – Premature cardiovascular events? Think familial hypercholesterolaemia
Author Antonio Vallejo-Vaz, of Imperial College, London, talks to medical journalist Dr Jane Stock about the FHSC and these findings.
87th EAS Congress, Maastricht
Reports and video interview with FHSC representatives
Dr. Antonio J. Vallejo-Vaz from the FHSC Co-ordinating Centre in Imperial College London, UK, discusses the survey of FH status in more than 60 countries participating in the FHSC Registry and some of the FH Lead Investigators discuss the status of FH care and new initiatives in FH that have been a direct consequence of participation in the FHSC Registry.
Improving FH care: the role of patient advocacy – A report from the EAS FH Studies Collaboration
Preceding the opening of the EAS Maastricht Congress, patient organisation representatives from FH Europe and FHSC researchers met to discuss opportunities and challenges in setting up a patient organisation. Opening this session, Professor Kausik Ray, lead of the EAS FHSC, emphasised the key role of patient advocacy in lobbying policy makers about FH.
While recognising that issues related to setting up an FH patient organisation may differ between countries, representatives from FH Europe highlighted key approaches that have proved successful.
Listen to some of the patient organisation representatives describing their situation and work in their respective country/area